MDCO News and Press, The Medicines Company From 05/20/19

Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett Writing about antibiotic innovators is a quandary for me because I have to balance between the need for investment profits for investors vs. my social responsibility. It's an inte...

Outlook Therapeutics (NASDAQ: OTLK ) +26%  as the company is poised to add to ONS-5010. More news on: Outlook Therapeutics, Inc., Orion Energy Systems, Inc, Sprint Corporation, Stocks on the move, Read more ...

The Medicines Company (NASDAQ: MDCO ) is up  9 %  premarket, albeit on only 461 shares, in reaction to preliminary data from the ongoing Phase 2 open-label extension study, ORION-3 , evaluating twice-a-year dosing with inclisiran sodium 300 mg in patients with high cardiovascul...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking David Einhorn's Greenlig...

Interim results from ongoing ORION-3 study demonstrated sustained lowering of LDL-C by more than 50 percent, with time-averaged absolute reductions of 59.4 mg/dL No material safety issues observed in the study Pivotal Phase 3 readouts for inclisiran expected in 3Q-2019 followed by ...

Noteworthy events during the week of May 12 - 18 for healthcare investors. More news on: Johnson & Johnson, Insmed Incorporated, Innovate Biopharmaceuticals, Inc., Healthcare stocks news, , Read more ...

Company management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from ongoing ORION-3 study The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, a...

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). A live audio webcast wil...

As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch ...

Antibiotic resistance is a growing global public health emergency. Melinta Therapeutics ( MLNT ) has decided to take up the critical mission of overcoming antibiotic resistance with their broad spectrum antibiotic portfolio. Unfortunately, the market doesn’t see the opportunity in addre...